Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: JAMA Intern Med. 2014 May;174(5):699–707. doi: 10.1001/jamainternmed.2014.87

Figure 1. Trends in Treatment with Erythropoiesis-Stimulating Agents Prior to End-Stage Renal Disease.

Figure 1

Figure 1

Figure 1

Panel A: Proportion of Patients Having Received Treatment with an Erythropoiesis-Stimulating Agent (any; epoetin alfa; darbepoetin alfa)

Panel B: Median Time from First Recorded Treatment with an Erythropoiesis-Stimulating Agent to End-Stage Renal Disease (in days)

Panel C: Adjusted Prevalence Rates of Erythropoesis-Stimulating Agent Use Prior to End-Stage Renal Disease (Referent: 1995)

Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid diabetes, estimated glomerular filtration rate and body mass index at end-stage renal disease.